Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert- Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference call on April 16 to review recent named-patient experience in patients suffering from multiple
Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The treatment resulted in an acceptable safety profile, with no observed clinical signs of early
Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology Strong balance sheet, bolstered by recent public offering, expected to fund operations into 2026 EMERYVILLE, Calif. , March 26, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc.
The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants The clinical study will be supported by cutting edge correlative studies funded through a parallel research
The paper reports on a series of 15 patients with severe rheumatological autoimmune diseases that were treated with a single infusion of CD19 CAR T-cell therapy by the European team with up to 29 months post-treatment follow up The Authors report the treatment appears to be feasible, safe, and
EMERYVILLE, Calif. , Feb. 12, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the closing of its upsized initial public
EMERYVILLE, Calif. , Feb. 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the pricing of its upsized initial public
The proprietary process, called Ingenui-T, utilizes whole blood from a standard blood draw The novel process is designed to elevate the CAR T cell patient experience by offering a less-invasive alternative to apheresis as well as substantial reduction of cost through a minimization of the CAR
The announcement follows the recent IND clearance for KYV-101 to be used in Kyverna’s KYSA-7 Phase 2 open-label, multicenter study KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases EMERYVILLE, Calif., January 19, 2024 – Kyverna
The seventh IND clearance will expand use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-7 clinical trial targeting a large patient demographic KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases EMERYVILLE, Calif.,